Recently a germline mutation in the proapoptotic gene BIM was associated with the resistance to tyrosine kinase inhibitors in chronic myeloid leukemia (CML) and epidermal growth factor receptor (EGFR) mutant NSCLC. The gene discussed is BCL2L11; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.